Barinthus Biotherapeutics plc Stock Price, News & Analysis

Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly known as Vaccitech plc, is a clinical-stage biopharmaceutical company pioneering novel T cell immunotherapeutic candidates. The company emerged from the University of Oxford’s Jenner Institute, one of the oldest and most esteemed vaccine research centers in the world.

Barinthus Biotherapeutics specializes in leveraging proprietary T cell immunotherapeutic technologies to address chronic infectious diseases, cancer, and autoimmunity. Their innovative platform technologies, including ChAdOx, MVA, SNAP-TI, and SNAP-CI, enable the development of diverse therapeutic candidates.

Key products in their pipeline include:

• VTP-300: An investigational immunotherapeutic candidate aimed at providing a functional cure for chronic Hepatitis B virus (HBV) infection.
• VTP-200: A non-invasive treatment for persistent high-risk human papillomavirus (HPV).
• VTP-850: A T cell therapy designed for recurrent prostate cancer.
• VTP-1000: A preclinical candidate for celiac disease.
• VTP-1100: A preclinical cancer candidate targeting HPV-related cancers.

Recent updates include successful clinical milestones in HPV and HBV programs, highlighted by promising data from the Phase 1b/2a trial of VTP-300 presented at the European Association for the Study of the Liver (EASL). The company is also preparing to present further data at the upcoming AASLD Liver Meeting 2023.

Financially, Barinthus Biotherapeutics reported extending its cash runway into the second quarter of 2025, reflecting operational agility and efficiency. The company’s founders, Professor Adrian Hill and Professor Sarah Gilbert, bring substantial scientific and regulatory expertise to the team, bolstering their innovative pursuits.

Barinthus Biotherapeutics continues to evolve, drawing inspiration from the mythological navigator Barinthus, guiding the immune system towards healing. For more information, visit www.barinthusbio.com.